MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13023-019-1077-6

Медицинская библиотека · Orphanet journal of rare diseases · 2019

Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.

Saffari Afshin, Brösse Ines, Wiemer-Kruel Adelheid, Wilken Bernd, Kreuzaler Paula, Hahn Andreas, Bernhard Matthias K, van Tilburg Cornelis M, Hoffmann Georg F, Gorenflo Matthias, Hethey Sven, Kaiser Olaf, Kölker Stefan, Wagner Robert, Witt Olaf, Merkenschlager Andreas, Möckel Andreas, Roser Timo, Schlump Jan-Ulrich, Serfling Antje, Spiegler Juliane, Milde Till, Ziegler Andreas, Syrbe Steffen

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Tuberous sclerosis complex (TSC) is a multisystem disease with prominent neurologic manifestations such as epilepsy, cognitive impairment and autism spectrum disorder. mTOR inhibitors have successfully been used to treat TSC-related manifestations in older children and adults. However, data on their safety and efficacy in infants and young children are scarce. The objective of this study is to assess the utility and safety of mTOR inhibitor treatment in TSC patients under the age of 2 years.

RESULTS

A total of 17 children (median age at study inclusion 2.4 years, range 0-6; 12 males, 5 females) with TSC who received early mTOR inhibitor therapy were studied. mTOR inhibitor treatment was started at a median age of 5 months (range 0-19 months). Reasons for initiation of treatment were cardiac rhabdomyomas (6 cases), subependymal giant cell astrocytomas (SEGA, 5 cases), combination of cardiac rhabdomyomas and SEGA (1 case), refractory epilepsy (4 cases) and disabling congenital focal lymphedema (1 case). In all cases everolimus was used. Everolimus therapy was overall well tolerated. Adverse events were classified according to the Common Terminology Criteria of Adverse Events (CTCAE, Version 5.0). Grade 1-2 adverse events occurred in 12 patients and included mild transient stomatitis (2 cases), worsening of infantile acne (1 case), increases of serum cholesterol and triglycerides (4 cases), changes in serum phosphate levels (2 cases), increase of cholinesterase (2 cases), transient neutropenia (2 cases), transient anemia (1 case), transient lymphopenia (1 case) and recurrent infections (7 cases). No grade 3-4 adverse events were reported. Treatment is currently continued in 13/17 patients. Benefits were reported in 14/17 patients and included decrease of cardiac rhabdomyoma size and improvement of arrhythmia, decrease of SEGA size, reduction of seizure frequency and regression of congenital focal lymphedema. Despite everolimus therapy, two patients treated for intractable epilepsy are still experiencing seizures and another one treated for SEGA showed no volume reduction.

CONCLUSION

This retrospective multicenter study demonstrates that mTOR inhibitor treatment with everolimus is safe in TSC patients under the age of 2 years and shows beneficial effects on cardiac manifestations, SEGA size and early epilepsy.

Для цитирования: Saffari Afshin, Brösse Ines, Wiemer-Kruel Adelheid, Wilken Bernd, Kreuzaler Paula, Hahn Andreas, Bernhard Matthias K, van Tilburg Cornelis M, Hoffmann Georg F, Gorenflo Matthias, Hethey Sven, Kaiser Olaf, Kölker Stefan, Wagner Robert, Witt Olaf, Merkenschlager Andreas, Möckel Andreas, Roser Timo, Schlump Jan-Ulrich, Serfling Antje, Spiegler Juliane, Milde Till, Ziegler Andreas, Syrbe Steffen. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.. Orphanet journal of rare diseases. 2019. DOI: 10.1186/s13023-019-1077-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.